Crinetics Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, marking its transition to a commercial-stage company, alongside pipeline advancements and a strong capital position.
NASDAQ
Crinetics Pharmaceuticals provides an update on its clinical-stage endocrine disease therapies, including the submission of a New Drug Application (NDA) to the FDA for paltusotine.
NASDAQ
10-K: Crinetics Pharmaceuticals Amends Lease, Files Annual Report and Updates Insider Trading Policy
Crinetics Pharmaceuticals amends its lease agreement, files its annual report on Form 10-K, and updates its insider trading policy, outlining key business activities and financial safeguards.